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Abstract  
BACKGROUND: Midkine (MK) induces inflammation and could inhibit inducible regulatory T cell differentiation. 
These reports suggest that MK may play a role in the pathogenesis of autoimmune disease including SLE, but 
data about MK in SLE patients was still limited, and the role of Midkine in SLE is largely unknown.  
AIM: The purpose of this study was to compare serum level MK in SLE patients and control, also analysed the 
relationship between the serum MK level and disease activity in SLE.  
METHODS: This cross-sectional study was conducted in Adam Malik Hospital from January-June 2017. 
Diagnosis of SLE was established according to the Systemic Lupus International Collaborating Clinics (SLICC) 
classification criteria, and disease activity was assessed using the Mexican Systemic lupus erythematosus 
disease activity index (MEX-SLEDAI). Subjects with evidence of malignancy and systemic disease (pulmonary, 
kidney, liver, metabolic disorder, etc.) were excluded. Data analysis was performed using SPSS 22nd version. P < 
0.05 was considered statistically significant.  
RESULTS: There were 90 subjects and divided into 2 groups: SLE patients group (n=40) and healthy control 
groups (n = 50). Midkine levels were increased in the serum of SLE patients compared by health control. There 
was a significant difference in the median serum Midkine levels between SLE patients and healthy control (P < 
0.001). Elevated Midkine serum levels were a significant difference between active disease and remission (P = 
0.018). 
CONCLUSION: Elevated Midkine serum level could be a marker of SLE disease activity and have a role in the 
pathogenesis of SLE. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Systemic lupus erythematosus (SLE) is a 
common systemic inflammatory autoimmune disease. 
The immune response in SLE can cause chronic 
inflammation leading to irreversible damage to organ 
systems [1]. SLE is characterised by many 
immunologic abnormalities, such as polyclonal 
activation of circulating B cells that generate a large 
number of autoreactive antibodies. SLE is also 
characterised by T lymphocyte abnormalities and 
immune complex (IC) deposition [2]. Cytokines that 
are derived from monocyte/macrophage play a key 
role in SLE pathogenesis. Cytokines collectively play 
key roles in the regulation of systemic inflammation, 
local tissue damage, and immunomodulation [3]. 
Midkine (MK) is a heparin-binding growth 
factor that was originally identified as the retinoic 
acid–response gene product. MK gene encodes it on 
chromosome 11 [4]. Midkine has a critical role in cell 
growth, survival, migration, angiogenesis, and 
carcinogenesis [5]. A higher midkine level in 
peripheral blood was associated with a poor outcome 
in patients with malignancies [6]. 
MK might modulate inflammatory responses 
[7]. MK induces inflammation via increasing 
leukocytes migration, induction of chemokine 
synthesis and preventing the development of 
regulatory T cells [8]. Midkine could inhibit inducible 
regulatory T cell differentiation by suppressing the 
development of tolerogenic dendritic cells [9]. It has 
been reported that MK level was elevated in the 
serum and synovial fluid of RA patients. These reports 
suggest that MK may play a role in the pathogenesis 
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of RA [10]. Data about MK in SLE patients was still 
limited. Role of midkine in SLE is largely unknown. 
The purpose of the present study was to compare the 
serum level of MK in SLE patients and control, also 
analysed the relationship between the serum MK level 
and disease activity in SLE. 
 
 
Methods 
 
This study was a cross-sectional study on 40 
consecutive SLE patients that were admitted to the 
Rheumatology Department and outpatient clinic of 
Adam Malik General Hospital and affiliated hospitals 
in Medan, Indonesia between January-June 2017. 
Diagnosis of SLE was established according to the 
Systemic Lupus International Collaborating Clinics 
(SLICC) classification criteria [11]. Subjects with 
evidence of malignancy and systemic disease 
(pulmonary, kidney, liver, metabolic disorder, etc.) 
were excluded. 
Disease activity was assessed for all the 
patients using the Mexican Systemic lupus 
erythematosus disease activity index (MEX-SLEDAI). 
MEX-SLEDAI score has a score range of 0 to 32, 
where the higher the score indicates, the more severe 
the activity of SLE disease. Active lupus is defined as 
the MEX-SLEDAI score > 5 [12]. Renal disorder in 
SLE patients according to SLICC classification criteria 
was proteinuria (> 0.5 g/24hr) or red blood cell casts 
[11]. Fifty age and sex-matched subjects were 
considered as a control group and were recruited from 
the relatives of the patients and healthcare providers 
in the hospital. The study was approved by the local 
ethics committee. All patients gave their informed 
consent before their inclusion in the study. 
Serum MK was measured in all enrolled 
subjects using ELISA kit (Glory Science, USA). The 
assay is based on a double-antibody sandwich ELISA 
technique for the quantitative assay of human MK in 
samples. In this technique, MK binds to the 
monoclonal antibody-enzyme well which is precoated 
with human MK monoclonal antibody, making a solid 
phase antibody. Then MK antibody is added and 
combines with Streptavidin-Horseradish Peroxidase 
(HRP) to form an immune complex. Following 
incubation, MK is removed during a wash step and 
then substrates A and B are added to the wells and 
the colour of the liquid changes into blue. The 
coloured product is formed in proportion to the amount 
of MK present in the sample. The reaction is 
terminated by addition of sulphuric acid. The 
concentration of MK in the samples is then 
determined by comparing the (optical density) OD of 
the samples to the standard curve and values were 
reported as pg/mL. 
Numerical data were expressed as mean ± 
SD, or median (interquartile range, IQR) if they were 
not in normal distribution. Data analysis was 
performed through univariate and bivariate analyses 
using the SPSS 22nd version (SPSS Inc., Chicago) 
with a 95% confidence interval. Bivariate analysis was 
performed using an Independent t-test and Mann-
Whitney U test with significance p<0.05. 
 
 
Results 
 
This study was followed by 90 subjects and 
divided into 2 groups: SLE patients group (n = 40) and 
Healthy control group (n = 50). There were 37 (92.5%) 
female patients and 3 (7.5%) male patients in group 
SLE. The mean age of the SLE group and healthy 
control group were 28.7 (6.1) and 27.3 (5.8) years 
respectively. The median of disease duration in group 
SLE was 4.5 (0-9) years. 24 patient (57.5%) in the 
SLE group had active disease (MEX-SLEDAI score > 
5) and 19 patients (47.5%) had renal disorder (Table 
1).  
Table 1: Basic and clinical characteristics of the subjects 
Characteristics SLE patients (n = 40) Healthy controls (n = 50) 
Gender 
a
 
 Female 
 Male 
 
37 (92.5%) 
3 (7.5%) 
 
46 (92%) 
4 (8%) 
Age (years)
 b
 28.7 (6.1) 27.3 ( 5.8) 
BMI (kg/m2)
 b
 22.7 (3.6) 24.4 (3.7) 
Disease duration (years)
 c
 4.5 (0 – 9) NA 
Active Disease
 a
 
 Yes 
 No 
 
24 (57.5%) 
16 (42.5%) 
NA 
Renal disorder
 a
 
 Yes 
 No 
 
19 (47.5%) 
21 (52.5%) 
NA 
N = total number of subjects; 
a
n (%); 
b
mean ± SD; 
c
median (min-max). 
 
Midkine levels were increased in the serum of 
SLE patients compared by health control. There was a 
significant difference in the median serum Midkine 
levels between SLE patients and healthy control (P < 
0.001). Patients SLE with active disease had midkine 
levels higher than remission group (660.2 ± 84.8) vs 
(596.9 ± 68.8) pg/ml, there was a significant difference 
in serum Midkine levels between active disease and 
remission (P = 0.018) but there was no significant 
difference in serum Midkine levels in renal disorder 
group (P = 0.092) (Table 2). 
Table 2: Comparison of serum midkine between SLE patients, 
active disease and renal disorder groups 
Group Number Midkine Levels (pg/ml) p 
SLE patients
a
 40 658 (502-795) <0.001 
Healthy controls 50 510 (370-750)  
Active Disease    
 Yes 24 660.2 ± 84.8 0.018 
 No 16 596.9 ± 68.8  
Renal Disorder
s
    
 Yes 19 658.4 ± 75.2 0.092 
 No 21 613.6 ± 87.5  
a 
Mean ± SD; 
b
Median (min-max). 
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SLE patients had serum Midkine levels higher 
than the control group; it can be seen in Figure 1, that 
median Midkine levels were 658 (502-795) pg/ml in 
SLE patient group and 510 (370-750) pg/ml in healthy 
control group.  
 
Figure 1: Boxplot diagram of Midkine level between SLE patients 
and controls 
 
SLE patients, especially with active disease, 
had serum Midkine levels higher than remission group 
because of elevated levels of autoimmune 
inflammatory response (Figure 2). 
 
Figure 2: Boxplot diagram of Midkine level between Active disease 
and remission 
 
Analysis result using the ROC curve obtained 
that cut off serum Midkine was >569pg/ml. The area 
under the curve (AUC) was 75.1% (p<0.001) with 
sensitivity and specificity of Midkine to predict 
diagnosis SLE were 70% and 60%. Positive 
Prediction Value (PPV), Negative Prediction Value 
(NPV), Positive Likelihood ratio (PLR), and Negative 
Likelihood Ratio (NLR) were 58.3%, 71.4%, 1.75 and 
0.5 respectively (Table 3). 
 
Figure 3: ROC curve of midkine level in the diagnosis of SLE 
 
 
 
Discussion 
 
SLE pathogenesis is closely related to the 
regulation of T lymphocytes. Regulatory T (Treg) cells 
are a subset of CD4+ T cells that maintain self-
tolerance by suppressing autoreactive lymphocytes. 
Treg cells are required to restore the disturbed 
immune homeostasis in SLE, and the failure of Treg is 
related to the persistent inflammatory cytokine. 
Defects in Treg cells or a lack of Treg cells are 
contributed to SLE pathogenesis [13] [14].  
Table 3: Accuracy of Midkine in the diagnosis of SLE 
 Cut off Sensitivity Specificity PPV NPV PLR NLR Accuracy 
Midkine >569 
pg/ml 
70% 60% 58.3% 71.4% 1.75 0.5 75.1% 
 
The previous study explained that there was a 
negative correlation between Tregs and disease 
activity of SLE [15]. 
Midkine (MK) derived from CD4+ T cells has a 
role in promoting cell proliferation, cell survival, 
migration cells, and antiapoptotic activity in the 
nervous system, cancer and inflammation area. In 
inflammation process, MK induces cytokines and 
modulates migration of neutrophils and macrophages. 
MK activates T splenocytes, Th1 cell differentiation 
and has functioned as a negative immune modulator 
of Tregs in peripheral lymph nodes [16]. Inhibition of 
MK leads to an increase in Treg expansion and then 
suppresses the autoreactive Th1 cell population thus 
causing the reduced severity of the autoimmune 
disease [8].  
This study examined Midkine serum level in 
SLE patients and healthy control. Median Midkine 
levels in this study were 658 (502-795) pg/ml and 510 
(370-750) pg/ml in SLE patient group and healthy 
control group. Our result was comparable to a study 
conducted by Wu GC et al., that reported median 
Midkine levels were 698.37 (516.09-767.07) pg/ml 
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and 628.22 (373.66-712.41) pg/ml in SLE patients and 
healthy control group. Our study result was consistent 
with Wu GC et al. that Midkine serum levels were 
significantly increased in SLE patient (P < 0.05) [17]. 
Elevated Midkine serum level also occurs in other 
autoimmune diseases such as rheumatoid arthritis 
and multiple sclerosis [10] [18]. 
Our result was consistent with Wu et al. that 
there was no significant difference in serum Midkine 
levels in SLE patients with and without the renal 
disorder (P > 0.05). But, there was a significant 
difference in serum Midkine levels between flare and 
remission in our result (P = 0.018) contrary to a 
previous study (P > 0.05) [17]. In Rheumatoid Arthritis 
(RA), Shindo et al. reported that MK level could be a 
biomarker of RA disease activity. There was 
correlation between serum MK and RA disease 
activity (DAS28-ESR) (r = 0.223, P = 0.019) [10]. 
Same result in Crohn’s Disease and Ulcerative Colitis 
that serum MK level was positive associated with 
Disease Activity Index [19] [20]. Midkine plays an 
important role in the pathogenesis of autoimmune 
diseases including SLE. Inhibiting Midkine can be 
useful to reduce the disease activity of autoimmune 
disease. In this study, cut off serum Midkine (> 569 
pg/ml) had a moderately accuracy to predict SLE 
(AUC > 70%) and a higher accuracy level than 
previous study [17]. 
This study has some limitations. MEX-
SLEDAI was used to assess the disease activity of 
SLE. MEX-SLEDAI was more simple but has a lower 
accuracy compared to the SLEDAI score. This study 
didn’t compare the difference of Midkine levels with 
blood disorders group or neuropsychiatry disorder 
group of SLE patients. Further studies are required 
with larger samples to determine the role of Midkine 
as a predictive marker to diagnose SLE. 
In conclusion, elevated Midkine serum level 
could be a marker of SLE disease activity and have a 
role in the pathogenesis of SLE. 
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